Resveratrol foda (501-36-0)

Resveratrol antioxidant ne wanda ke faruwa a cikin ɗabi'a wanda aka samo a cikin jan inabi 'ya'yan itace. Resveratrol foda an san shi da kewayon fa'idodin kiwon lafiya da fa'idodin nootropic. Resveratrol ya fi mai da hankali a cikin konkoma karãtunsa fãtun da tsaba na inab andbi da 'ya'yan itãcen marmari. Wadannan bangarorin innabi suna hade a cikin ferment na jan giya, saboda haka musamman mahimmancin resveratrol.

Kodayake, yawancin binciken da aka yi akan resveratrol an yi shi ne a cikin dabbobi da shagunan gwaji ta amfani da ɗimbin yawa na fili.

Daga iyakataccen bincike a cikin mutane, mafi yawan sun mayar da hankali ne a kan ƙarin siffofin mahaɗin, a cikin mafi yawan abubuwan da za ku iya samu ta hanyar abinci.

Maganar farko game da resveratrol ta kasance a cikin wani labarin Jafananci a cikin 1939 ta hannun Michio Takaoka, wanda ya ware ta daga kundin Veratrum, grandiflorum iri-iri, kuma daga baya, a 1963, daga tushen knotweed na Jafananci.

Resveratrol ya tsoma baki tare da dukkan matakai uku na cutar sankara - farawa, haɓakawa da ci gaba. Gwaje-gwaje a cikin al'adun kwayoyi na nau'ikan daban-daban da keɓaɓɓun tsarin ƙananan ƙwayoyin cuta a cikin vitro yana nuna hanyoyin da yawa a cikin aikin maganin magunguna na resveratrol. Waɗannan hanyoyin sun haɗa da sauya yanayin tasirin NF-kB, hanawa cytochrome P450 isoenzyme CYP1A1 (kodayake wannan ba zai dace da aikin ba da aikin CYP1A1 ba na procarcinogen benzo (a) pyrene), canje-canje a cikin ayyukan inrogenic da magana da aiki. na cyclooxygenase (COX) enzymes.

An bayar da rahoton Resveratrol yana da tasiri a kan lalacewar kwayar neuronal da mutuwar kwayar halitta, kuma a ka'ida na iya taimakawa daga cututtuka irin su cutar Huntington da cutar Alzheimer. Bugu da ƙari, wannan har yanzu ba a gwada shi cikin ɗan adam don wata cuta ba.

Bincike a Kwalejin Kimiyya ta Jami'o'in Arewa maso gabashin Ohio da Jami'ar Jihar Ohio ya nuna cewa resveratrol yana da aikin inhibitory kai tsaye akan cututtukan zuciya kuma yana iya hana ci gaban cututtukan zuciya.

Lura cewa resveratrol bioavailability ya dogara da siffofin haɗin gwiwa: glucuronate da sulfonate, duk da cewa yawancin karatun in vitro suna amfani da nau'in aglycone na resveratrol ('aglycone' yana nufin ba tare da kwayar sukari da aka haɗe ba, kamar yadda yake a cikin adadi a cikin wannan labarin).

Resveratrol na iya hana isashshewar garkuwar jiki na karancin sinadarin lipoprotein, kuma yana da tasirin gaske wajen hana cutar cututtukan zuciya, daji, riga-kafi da kuma rigakafi. Babban aikinta shine kaddarorin antioxidant.

Magungunan zuciya. Zai iya rage mai mai zafi da kuma hana cututtukan zuciya. Hakanan yana da tasiri ga cutar kanjamau.

Antioxidants da aiki a cikin anti-mai kumburi, antithrombotic, anti-cancer, anti-cancer, anti hyperlipidemia da antibacterial.

Anti-tsufa, daidaita lipid na jini, kariyar zuciya, maganin hepatitis.

Resveratrol wani phytoalexin ne da aka kirkira ta tsire-tsire da dama tare da cututtukan daji, anti-mai kumburi, rage sukari da jini da sauran tasirin ciwan zuciya.

A matsayin karin kayan abinci, sai a dauki 250mg sau biyu a rana, ko kuma kamar yadda kwararren likitan ku ya umarce ku. An ba da shawarar a sha shi tare da abinci don ƙara yawan ƙwayar jiki. Hakanan yana da kyau a ɗauka tare da sauran kayan ɓaure ko tare da 'ya'yan inabi masu tsami, saboda wannan yana sa sakamakon Resveratrol ya kasance mafi ma'ana. Ana buƙatar ma'aunin milligram don auna daidai sashi.

COA

• ] Timmers S., Konings E., Bilet L, et al. Taƙaitawa ta Calorie-kamar Sakamakon kwanaki 30 na ƙarin Resveratrol na Haɓakawa akan Maganin Harkokin Makamashi da Bayanan Magani a cikin Oban Adam. Hanyar Halittar Kwayar cuta ta 2011; 14: 612-622
• Powell, RG, et al.: Phytochemistry, 35, 335 (1994), Jeandet, P., et al.: J. Phytopathol., 143, 135 (1995), Mattivi, F., et al.: J. Agric . Chem Abinci., 43, 1820 (1995)
• Leiro J, Arranz JA, Fraiz N, Sanmartín ML, Quezada E, Orallo F (2005). "Tasirin cis-resveratrol akan kwayoyin halittar da ke cikin tasirin nukiliya kappa B sigina". Int. Immunopharmacol. 5 (2): 393–